Topic Hub
22 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 22 of 22 clinical reviews.
A clinician-level guide to using inclisiran (Leqvio) after bariatric surgery, covering pharmacokinetics, dosing, LDL-C targets, drug interactions, and real-world considerations for post-bariatric patients with ASCVD or familial hypercholesterolemia.
Read clinical reviewA clinical deep-dive into inclisiran (Leqvio) use in patients with autoimmune disease, covering safety data from ORION trials, immunogenicity findings, dosing considerations, and practical guidance for rheumatology-cardiology co-management.
Read clinical reviewA clinical deep-dive into inclisiran's effects on kidney function, including ORION trial renal safety data, CKD dosing guidance, and emerging renoprotective signals from lipid lowering.
Read clinical reviewDoes inclisiran (Leqvio) affect appetite or food cravings? A physician-reviewed deep dive into ORION trial data, the PCSK9 pathway, and what patients on twice-yearly injections genuinely experience.
Read clinical reviewA physician-reviewed deep dive into inclisiran (Leqvio) and its effects on bone mineral density, osteocalcin, and fracture risk, drawing on ORION trial data, PCSK9 biology, and current ACC/AHA guidelines.
Read clinical reviewA physician-level review of the inclisiran (Leqvio) cancer risk signal: ORION trial data, FDA labeling, post-marketing surveillance, and how to counsel patients with ASCVD or familial hypercholesterolemia.
Read clinical reviewA physician-reviewed deep dive into inclisiran's long-term cardiovascular impact, covering ORION trial data, LDL-C reductions, MACE outcomes, and what twice-yearly dosing means for patients with ASCVD or familial hypercholesterolemia.
Read clinical reviewA clinical deep-dive into inclisiran (Leqvio) and cognitive function. Covers ORION trial data, PCSK9 inhibitor cognitive safety evidence, FDA labeling, and how to counsel patients asking whether Leqvio affects memory or thinking.
Read clinical reviewA physician-level comparison of branded Leqvio (inclisiran) versus compounded inclisiran, covering FDA approval status, ORION trial efficacy data, safety, cost, and how to choose between them.
Read clinical reviewA GRADE-graded review of inclisiran (Leqvio) evidence from ORION-1 through ORION-11, covering LDL-C reduction magnitude, cardiovascular outcome data, dosing schedule, and where the certainty of evidence is high, moderate, or low.
Read clinical reviewDoes inclisiran (Leqvio) cause hair loss or skin reactions? A physician-reviewed deep-dive into ORION trial data, FDA labeling, and what to expect at every injection visit.
Read clinical reviewA clinician-level review of inclisiran (Leqvio) liver function impact, covering ALT/AST data from ORION-10, ORION-11, and ORION-3, hepatic metabolism, and what to monitor before and after dosing.
Read clinical reviewA physician-reviewed look at inclisiran (Leqvio) and its mental health and mood effects, drawing on ORION-10, ORION-11, and neurocognitive safety data from primary literature.
Read clinical reviewA physician-level review of inclisiran (Leqvio) dosing regimens, the evidence base for standard twice-yearly dosing, and whether any microdosing protocols exist or are supported by current data.
Read clinical reviewA clinician-level review of inclisiran (Leqvio) muscle preservation strategies, covering mechanism, trial data from ORION-10/11, monitoring protocols, and practical management of statin-intolerant patients switching to or combining inclisiran.
Read clinical reviewWhy some patients see blunted LDL-C reductions on inclisiran (Leqvio) and what clinicians can do about it. Covers adherence, statin interactions, PCSK9 genetics, add-on therapies, and re-dosing protocols backed by ORION trial data.
Read clinical reviewA clinician-level guide to managing inclisiran (Leqvio) around surgery, including hold windows, LDL-C rebound kinetics, redosing timing, and perioperative cardiovascular risk considerations.
Read clinical reviewDoes stopping Leqvio (inclisiran) cause a cholesterol rebound? Explore the clinical evidence from ORION trials, LDL-C kinetics after discontinuation, and what physicians recommend for patients who pause or stop treatment.
Read clinical reviewEvidence-based guidance on when and how to restart inclisiran (Leqvio) after acute illness, surgery, or hospitalization. Includes dosing timelines, LDL-C monitoring, and ORION trial data.
Read clinical reviewA clinician-level review of inclisiran (Leqvio) seasonal dosing, LDL-C fluctuation by season, cold-chain storage, and scheduling strategy for twice-yearly injections, with primary-literature citations throughout.
Read clinical reviewDoes inclisiran (Leqvio) affect sleep architecture? A clinician-level review of ORION trial data, statin-comparison sleep biology, and what patients on twice-yearly dosing should know.
Read clinical reviewEverything clinicians and patients need to know about timing Leqvio (inclisiran) doses around travel, timezone changes, and real-world scheduling. MD/PharmD-level depth with primary-literature citations.
Read clinical review